Welcome to our dedicated page for INmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies that leverage the body’s innate immune system to fight cancer and other diseases. The company has a robust pipeline of product candidates, including INKmune™, INB03™, XPro™, and LIVNate™.
The company’s leading product, INKmune™, is designed to prime a patient’s natural killer (NK) cells to target and eliminate cancer cells that remain after initial treatment, thereby preventing relapse. By enhancing the functionality of NK cells, INKmune™ aims to boost the body’s ability to control residual disease, potentially extending patient survival.
INmune Bio’s INB03™ is a dominant-negative tumor necrosis factor (DN-TNF) inhibitor targeting high-risk breast cancers expressing MUC4 and triple-negative breast cancer (TNBC). Recent data presented at the American Association of Cancer Research in San Diego highlighted INB03™’s potential to decrease T cell and macrophage immune checkpoint proteins and reduce the metastatic potential of TNBC.
The company has also achieved significant milestones with XPro™, a treatment for Alzheimer’s Disease. INmune Bio recently announced the successful completion of the extended stability validation for continuous storage of XPro™ in solution, confirming its 24-month stability. The company is preparing for Phase III trials and commercial applications, leveraging established global distribution systems.
In addition, INmune Bio has entered into definitive agreements for the sale and purchase of nearly 1 million shares of its common stock and warrants, generating gross proceeds of approximately $9.7 million. These funds are earmarked to support ongoing clinical trials, including the Phase 2 trial for Alzheimer’s Disease and the Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC) using INKmune™.
The company’s management has focused on ensuring the safety and efficacy of their treatments. Recently, INKmune™ has shown promising results in initial clinical trials for mCRPC, with no significant adverse events reported, and approvals to proceed with further dosing cohorts.
For investors and stakeholders, INmune Bio provides a unique investment opportunity, combining cutting-edge science with a commitment to improving patient outcomes through innovative immunotherapy solutions. For more information, visit www.inmunebio.com.
FAQ
What is the current stock price of INmune Bio (INMB)?
What is the market cap of INmune Bio (INMB)?
What is INmune Bio Inc.'s primary focus?
What is INKmune™?
What recent achievements has INmune Bio reported?
What is the significance of INB03™?
How does INmune Bio plan to use the recent funding?
What are the key components of INmune Bio’s product platforms?
What ongoing clinical trials are INmune Bio conducting?
How does INKmune™ work?
Is INmune Bio’s technology approved by the FDA?
How can investors get more information about INmune Bio?
